---
title: "Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Real-world evidence questions"
description: "Real-world evidence questions on Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Gardasil 9: is provider recommendation associated with HPV vaccine initiation (2021 meta-analysis)? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/real-world-evidence"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination: Real-world evidence questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Gardasil 9](https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf)

Questions that apply to every indication of Gardasil 9 are on [Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), all indications](https://www.evicenter.com/medical-information/gardasil-9).

## Real-world evidence

<a id="gardasil9-provider-recommendation"></a>

### Gardasil 9: is provider recommendation associated with HPV vaccine initiation (2021 meta-analysis)?

Applies to: HPV vaccine initiation among US adolescents and adults (2021 meta-analysis cited by the manufacturer)

> “A provider recommendation to patients 11 years and older was associated with increasing the odds of initiating HPV vaccination ~tenfold (pooled OR=10.1, 95% CI, 7.6, 13.4).<sup>1,a</sup>”

Source: [GARDASIL 9: Recommending GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to Appropriate Patients, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/resources/patient-pd/#:~:text=A%20provider%20recommendation%20to%20patients,%28pooled%20OR%3D10.1%2C%2095%25%20CI%2C%207.6%2C)

> “<sup>a</sup>In a meta-analysis published in 2021, pooled analysis of 45 studies yielded 59 effect sizes (n=226,224) examining provider recommendation and HPV vaccine initiation among US adolescents aged 11-17 years and adults.<sup>1</sup>”

Source: [GARDASIL 9: Recommending GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to Appropriate Patients, captured 2026-11-13](https://www.merckvaccines.com/gardasil9/resources/patient-pd/#:~:text=a%20meta%2Danalysis%20published%20in%202021%2C,adolescents%20aged%2011%2D17%20years%20and)

## Related pages
- [Medical information: Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant): Human papillomavirus vaccination](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination)
- [Indication](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/safety)
- [Specific populations](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/gardasil-9--human-papillomavirus-vaccination/guidelines)
